Connor, Clark & Lunn Investment Management (CC&L)
MACK

Connor, Clark & Lunn Investment Management (CC&L)’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,405
Closed -$177K – 1609
2023
Q2 		$177K Buy
+14,405
New +$180K ﹤0.01% 1204
2020
Q1 		– Sell
-107,098
Closed -$337K – 1248
2019
Q4 		$337K Hold
107,098
– – ﹤0.01% 737
2019
Q3 		$481K Sell
107,098
-90,982
-46% -$455K ﹤0.01% 692
2019
Q2 		$943K Sell
198,080
-7,535
-4% -$35.7K 0.01% 581
2019
Q1 		$1.12M Sell
205,615
-9,278
-4% -$42.6K 0.01% 505
2018
Q4 		$653K Sell
214,893
-3,178
-1% -$11K ﹤0.01% 643
2018
Q3 		$914K Sell
218,071
-4,067
-2% -$17.1K 0.01% 580
2018
Q2 		$858K Buy
222,138
+40,048
+22% +$266K ﹤0.01% 643
2018
Q1 		$1.15M Buy
182,090
+69,429
+62% +$575K 0.01% 463
2017
Q4 		$909K Buy
112,661
+67,176
+148% +$626K 0.01% 527
2017
Q3 		$520K Buy
45,485
+35,339
+348% +$371K ﹤0.01% 637
2017
Q2 		$99K Buy
+10,146
New +$207K ﹤0.01% 785
2016
Q3 		– Sell
-13,892
Closed -$589K – 962
2016
Q2 		$589K Sell
13,892
-48,412
-78% -$2.64M ﹤0.01% 556
2016
Q1 		$4.1M Sell
62,304
-49,023
-44% -$2.56M 0.03% 246
2015
Q4 		$6.92M Sell
111,327
-17,660
-14% -$1.24M 0.06% 177
2015
Q3 		$8.64M Sell
128,987
-1,367
-1% -$112K 0.07% 140
2015
Q2 		$12.7M Sell
130,354
-3,444
-3% -$328K 0.12% 96
2015
Q1 		$12.5M Buy
133,798
+39,795
+42% +$3.39M 0.11% 96
2014
Q4 		$8.36M Buy
94,003
+73,985
+370% +$5.39M 0.07% 122
2014
Q3 		$1.38M Buy
+20,018
New +$1.07M 0.01% 257

Other funds holding MACK

WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $292M AUM 36.12% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MACK Position: Q3 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2023, closing a stake of 14,405 shares — an estimated $177K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MACK in Q3 2014 and held it in 20 quarters. The position peaked at $12.7M in Q2 2015. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 14,405 Merrimack Pharmaceuticals, Inc. shares in Q3 2023, an estimated $177K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 20 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Merrimack Pharmaceuticals, Inc. position peaked at $12.7M in Q2 2015.
  • 63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2023, filed 13 Nov 2023.